CJC-1295 Purity Standards & COA Requirements
Navigating peptide quality requirements demands rigorous analytical verification, particularly for complex growth hormone secretagogues. This technical guide outlines the essential Certificate of Analysis (COA) parameters, High-Performance Liquid Chromatography (HPLC) standards, Mass Spectrometry (MS) verification, and endotoxin thresholds required for CJC-1295 in laboratory research applications.
Quick answer
Navigating peptide quality requirements demands rigorous analytical verification, particularly for complex growth hormone secretagogues. This technical guide outlines the essential Certificate of Analysis (COA) parameters, High-Performance Liquid Chromatography (HPLC) standards, Mass Spectrometry (MS) verification, and endotoxin thresholds required for CJC-1295 in laboratory research applications.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is a synthetic tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH).
- For research institutions, a [Certificate of Analysis](/research-peptides/what-is-a-coa-for-peptides) (COA) serves as the primary document confirming a peptide's chemical validity, purity, and safety profile.
- High-Performance Liquid Chromatography (HPLC) is the gold standard for determining the chemical purity of synthetic peptides.
- While HPLC quantifies purity by separating chemical species, Mass Spectrometry (MS) confirms molecular identity by measuring the exact mass-to-charge ratio (m/z) of the peptide.
Chemical Structure and Research Profile of CJC-1295
CJC-1295 is a synthetic tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH). Acting as a selective GHRH analog, the compound binds to the GHRH receptor on anterior pituitary somatotrophs to stimulate endogenous growth hormone (GH) secretion. In preclinical literature, CJC-1295 is widely studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research, metabolic signaling, and cellular regeneration models.
The primary structural innovation in CJC-1295 involves four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) relative to the native GHRH sequence. These modifications protect the peptide backbone against enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), dramatically extending its terminal half-life compared to endogenous GHRH(1-29). When evaluating this compound in vitro or in animal models, investigators must ensure that the chemical identity matches strict sequence specifications, as structural degradants or truncated sequences can significantly alter receptor affinity and biological activity.
The Importance of a Third-Party Certificate of Analysis (COA)
For research institutions, a Certificate of Analysis (COA) serves as the primary document confirming a peptide's chemical validity, purity, and safety profile. Obtaining a lot-specific COA from an independent, ISO 17025-accredited analytical laboratory is essential to prevent experimental skew caused by synthesis impurities, truncated side-products, or solvent residues.
A valid cjc-1295 purity coa must contain detailed primary data rather than summary statements. Principal investigators should verify that the document includes high-resolution HPLC chromatograms, clear raw baseline integration tables, electrospray ionization mass spectrometry (ESI-MS) spectra, and quantified bacterial endotoxin measurements. Relying on unverified supplier claims without lot-matched COAs introduces unacceptable variability in preclinical trial outcomes.
HPLC Purity Analysis: Interpreting Chromatography Thresholds
High-Performance Liquid Chromatography (HPLC) is the gold standard for determining the chemical purity of synthetic peptides. Reverse-phase HPLC (RP-HPLC) separates CJC-1295 from closely related synthetic impurities, such as stereoisomers, deletion sequences, and incomplete deprotection byproducts generated during solid-phase peptide synthesis (SPPS).
When evaluating a CJC-1295 COA, researchers should look for a singular, well-defined main peak representing the target sequence. A standard laboratory specification requires an HPLC purity threshold of ≥98.0%. The area under the curve (AUC) calculation for the primary peak indicates the relative concentration of intact CJC-1295. Secondary peaks representing related substances must remain below strict individual thresholds (typically <0.5% per impurity) to prevent off-target receptor interaction in cell culture or animal assays.
Mass Spectrometry (MS) and Sequence Identity Verification
While HPLC quantifies purity by separating chemical species, Mass Spectrometry (MS) confirms molecular identity by measuring the exact mass-to-charge ratio (m/z) of the peptide. CJC-1295 without Drug Affinity Complex (DAC) possesses a theoretical monoisotopic molecular weight of 3367.97 Da, whereas CJC-1295 with DAC includes a maleimidopropionic acid linker resulting in a distinct molecular weight.
Electrospray ionization mass spectrometry (ESI-MS) reports multiple charge states (such as [M+3H]3+ or [M+4H]4+) that are deconvoluted to determine the precise observed mass. A pass specification on a COA requires the experimentally determined mass to match the theoretical mass within a tolerance of ±1.0 Da. Mass spectrometry also detects deletion sequences—peptides missing individual amino acids—which might co-elute with the target peak on standard chromatographic runs.
Endotoxin Limits and Bioburden Verification in Research Settings
Bacterial endotoxins, primarily lipopolysaccharides (LPS) derived from Gram-negative bacterial cell walls, pose a significant risk in preclinical peptide applications. In cellular assays, elevated endotoxin levels induce inflammatory cytokine cascades (such as TNF-alpha and IL-6) that mask or alter the true biological effects of a GHRH analog. In animal models, contaminated peptides can trigger acute phase responses, fever, or septic reactions.
PX1 Research enforces stringent quality limits using Limulus Amebocyte Lysate (LAL) or recombinant Factor C testing protocols detailed in our endotoxin testing guidelines. High-purity CJC-1295 intended for sensitive laboratory research must demonstrate endotoxin levels under <0.01 EU/mg (or <0.1 EU/mg depending on assay sensitivity requirements). Ensuring low bioburden is critical for reproducible in vitro cell signaling research and in vivo microinjection studies.
Comparative Analysis: CJC-1295 vs. Other Secretagogues
When designing protocols around the growth hormone axis, investigators often evaluate CJC-1295 alongside other GHRH derivatives and growth hormone secretagogue receptor (GHSR) agonists. Understanding the analytical and functional distinctions between these compounds is crucial for proper experiment selection.
In preclinical models, researchers frequently compare the GHRH analog CJC-1295 No DAC against classic GHRH fragments like sermorelin or longer-chain analogs like tesamorelin, as well as selective GHRP receptor agonists such as ipamorelin. While sermorelin mimics native GHRH(1-29) with a rapid enzymatic clearance rate, CJC-1295 incorporates structural substitutions that resist DPP-IV degradation. When combined with GHRP class peptides like ipamorelin in vitro, CJC-1295 demonstrates synergistic GH release by acting on distinct pituitary receptor pathways. Comprehensive overview data on these pathways can be explored in our GHRH analogs overview.
Solid-Phase Peptide Synthesis and TFA Removal
CJC-1295 is produced via automated Solid-Phase Peptide Synthesis (SPPS) using Fmoc chemistry. Following assembly of the 29-amino acid chain on a solid resin support, the peptide is cleaved using trifluoroacetic acid (TFA). This process leaves residual TFA salts bound to basic amino acid side chains (such as lysine and arginine residues).
Excessive TFA concentrations can lower culture medium pH or exert cytotoxicity in cell-based assays. High-grade research manufacturing incorporates counterion exchange protocols—converting TFA salts into acetate or chloride forms—or subjects the crude material to repetitive preparative RP-HPLC cycles. A thorough COA should list residual solvent analysis and moisture content (determined via Karl Fischer titration) to ensure the target peptide concentration is accurate when weighing dry mass for solubilization.
Laboratory Reconstitution and Storage Parameters
Maintaining chemical stability post-synthesis requires strict laboratory handling protocols. CJC-1295 is supplied as a sterile lyophilized cake or powder to optimize long-term shelf life. Lyophilization removes residual water, preventing hydrolysis reactions that degrade the peptide chain during room-temperature transport.
Upon arrival, un-reconstituted CJC-1295 vials should be stored in a lab freezer at -20°C or -80°C, protected from light and moisture. For reconstitution in laboratory settings, researchers typically use bacteriostatic water or sterile phosphate-buffered saline (PBS) depending on assay requirements. Repeated freeze-thaw cycles must be avoided to prevent aggregation and loss of potency. Detailed volumetric calculations and step-by-step procedures can be verified using our peptide reconstitution guide.
Quality Assurance at PX1 Research
PX1 Research enforces rigorous quality control standards across all catalog compounds. Every batch of CJC-1295 is USA-synthesized in GMP-compliant facilities and undergoes complete characterization by independent ISO 17025 accredited testing laboratories. We maintain transparent lot-to-lot traceability to ensure consistency across longitudinal research programs.
Our multi-stage verification protocol checks purity via high-resolution HPLC, confirms sequence identity via mass spectrometry, and measures bioburden through LAL endotoxin testing. Research facilities seeking bulk quantities or verified reference standards can review ordering frameworks via our wholesale accounts portal or explore technical documentation in the PX1 research library.
Frequently Asked Questions
What is the baseline purity standard required on a CJC-1295 COA?
A high-grade CJC-1295 Certificate of Analysis requires an HPLC purity threshold of ≥98.0%. The COA must include the full chromatogram showing clear baseline resolution and an integration table confirming that total synthesis impurities remain below 2.0%.
How does CJC-1295 without DAC differ structurally from CJC-1295 with DAC on mass spec?
CJC-1295 without DAC (Tetrasubstituted GRF 1-29) has a monoisotopic mass of 3367.97 Da. CJC-1295 with DAC includes a maleimidopropionic acid linker attached to the C-terminus, adding 629.3 Da to the total mass, resulting in a distinct peak profile on mass spectrometry.
Why is endotoxin testing critical for CJC-1295 used in cell culture models?
Bacterial endotoxins (LPS) activate TLR4 receptors in immune and somatic cells, causing non-specific inflammatory responses and cytokine release. In research assays evaluating growth hormone secretagogues, elevated endotoxins mask specific receptor signaling and distort experimental data.
What analytical technique verifies the exact molecular weight of CJC-1295?
Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) is used to verify molecular weight. The COA reports deconvoluted mass matching the theoretical molecular mass within ±1.0 Da.
How should CJC-1295 lyophilized powder be stored upon delivery to the laboratory?
Lyophilized CJC-1295 should be stored at -20°C for short-to-medium term stability, or -80°C for long-term storage. Vials must be kept sealed in desiccated containers to prevent moisture absorption prior to reconstitution.
What solvent is recommended for reconstituting CJC-1295 for in vitro testing?
Sterile bacteriostatic water (0.9% benzyl alcohol) or sterile laboratory-grade saline/PBS is commonly used for solubilization. Solvent choice depends on the specific requirements of the cellular assay or analytical instrument protocol.
What level of residual TFA is acceptable in research-grade CJC-1295?
Standard lyophilized peptides contain minor trifluoroacetate counterion residues. For sensitive cell culture applications, residual TFA content should ideally be documented at <1% to avoid cell toxicity or unwanted pH shifts in unbuffered media.
How does PX1 Research ensure lot-to-lot consistency for laboratory accounts?
PX1 Research subjects every individual synthesis batch to third-party HPLC/MS and LAL endotoxin analysis in an ISO 17025 accredited laboratory. COAs are published per lot, providing complete chemical transparency before material is cleared for distribution.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.